Chemours Co — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Chemours reported Q3 2026 net sales of $1,540M (up 3% YoY) and net income of $196M ($1.29/share), vs. $46M ($0.31/share) prior year. The Q3 income benefited from a $150M PFAS insurance proceeds MOU with New Jersey (recorded as SG&A reduction). Adjusted EBITDA grew 6% to $200M. The company settled litigation with North Carolina and 11 local entities (terms not quantified in text); completed $340M sale of Kuan Yin property. Gross debt $3.9B; net leverage 4.3x. FY 2026 guidance: ~2% sales growth, Adjusted EBITDA $775–800M, free cash flow >15% conversion.
Why this rating
Q3 core EBITDA growth modest (+6%). Large litigation settlement and $150M insurance recovery are one-time, non-recurring items masking operational challenge: TSS segment EBITDA down 30% YoY. North Carolina settlement amount undisclosed. Asset sale ($340M) is deleveraging but non-operational. Relative to $1.7B market cap, incremental EBITDA is ~7% of company value; ordinary quarterly result with significant litigation tail risk unresolved.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.